Medications

FDA approves first targeted therapy for HER2-low breast cancer

The U.S. Food and Drug Administration has approved Enhertu (am-trastuzumab-deruxtecan-nxki), an intravenous infusion treatment for patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-low ...

Oncology & Cancer

New injectable gel offers promise for tough-to-treat brain tumors

Like the hardiest weed, glioblastoma almost always springs back—usually within months after a patient's initial brain tumor is surgically removed. That is why survival rates for this cancer are just 25 percent at one year ...

Neuroscience

Developing a new human cell line to study blinding eye disorders

Under the direction of Boyd Professor Nicolas Bazan, MD, Ph.D., scientists at LSU Health New Orleans Neuroscience Center of Excellence have developed a new, experimental human cell line from retinal pigment epithelial cells. ...

page 1 from 40